Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...
Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...
Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its VENTANA TROP2 (EPR20043) RxDx...
Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials
China-based device giant United Imaging Healthcare (UIH, SHA: 688271) released its 2024 financial report, recording...
Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
WuXi AppTec Reports 21.0% YOY Revenue Growth in Q1 2025
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its financial report...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...
NMPA Issues New Quality Management Standards for Online Medical Device Sales
The National Medical Products Administration (NMPA) has released the “Announcement on Quality Management Standards for...
BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
NHSA Launches Intelligent Supervision Reform Pilot in Designated Medical Institutions
The National Healthcare Security Administration (NHSA) has released a notification to implement an intelligent supervision...
Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...